Physician profile
Yun Xia
NPI 1104188747
$438.04
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $311 · 2020: $128.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $111.80 | 2019-2020 | |
| Pfizer INC. | $69.95 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $50.34 | 2019 | |
| Novo Nordisk INC | $47.45 | 2019 | |
| Merck Sharp & Dohme LLC | $31.83 | 2019 | |
| Sanofi-Aventis U.S. LLC | $31.19 | 2019 | |
| Lifescan, INC. | $23.68 | 2019 | |
| Astellas Pharma US INC | $22.81 | 2019 | |
| Janssen Biotech, INC. | $17.94 | 2019 | |
| Abbvie INC. | $16.66 | 2019 | |
| Shire North American Group INC | $14.39 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yun Xia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.